Gynecologic Oncology (GYNPTH) Pathways

These four pathways are composed of paired tumor-germline testing for patients with gynecological cancers, following the UWMC Gynecological Oncology Pathways. The pathways include one or more tests from the following list, as determined by the agreed-upon diagnostic pathway: BROCA Paired Tumor Panel [BROCOP], targeted KRAS Mutations (DNA) [KRAS], BRAF Mutations [BRAF], MLH1 Promoter Hypermethylation [MLH1MT], Microsatellite Instability [MSI], UW OncoPlex Single Gene [OPG], UW OncoPlex Cancer Gene Panel [OPX], PDL1 IHC (send out).

These diagnostic pathways are defined by tumor type. See links below for testing specifics for each pathway:

• Ovarian, Fallopian, Peritoneal Pathway
• Primary Endometrial Carcinoma Pathway
• Recurrent + Metastatic Endometrial Carcinoma or Rare Tumor Pathway
• Recurrent + Metastatic Cervical, Vulvar, Vaginal Pathway

Specimen Requirements

Peripheral blood for Tumor Test Comparator Sample [OPCOMP] should be submitted.

Tumor tissue will be acquired by the laboratory.

The test order Gynecological Oncology Pathway [GYNPTH] will be initiated per the tumor type Gynecological Oncology Pathway (see above for diagnostic pathway details).

Requisitions and Contact Information

Requisitions

• Clinical Genetics Requisition
• TRONG Pathways Requisition
• PhenoPath requisition for PDL1 testing

Instructions: Complete the appropriate requisition(s) and submit according to requisition instructions. The laboratory will start acquiring tissue when a completed requisition is received.

Contact Information

For pathway specific questions, including ordering help, please contact: genelab@uw.edu.

For pre-authorization questions, please contact: ngsbill@uw.edu.

For pre-analytical specimen type questions, please contact: teamgps@uw.edu.

Fax number: (206) 616-4584